Therapeutic Response

CD33 + status confers therapeutic sensitivity to Cytarabine in combination with Daunorubicin and Gemtuzumab ozogamicin in patients with Acute Myeloid Leukemia.

Statements

Source and description
Mylotarg (gemtuzumab ozogamicin) [product information]. EMA. The European Medicines Agency (EMA) has authorized gemtuzumab ozogamicin in combination with cytarabine and daunorubicin for the treatment of patients aged 15 years and above with previously untreated, de novo CD33-positive acute myeloid leukemia (AML), except acute promyelocytic leukaemia (APL).